Shares in Verve Therapeutics (NASDAQ: VERV) soared 80.5% this week on the news of an agreement for Eli Lilly (NYSE: LLY) to ...

Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.

Secretary of Agriculture Brooke Rollins on Wednesday announced a plan to enhance the agency's ability to detect, control and ...

While the results were an important proof point for so-called anti-myostatin drugs, Scholar Rock executives indicated the ...

Eli Lilly just dropped $1 billion—plus a $300 million bonus if trials go well—on gene therapy firm Verve, aiming to spice up ...

U.S. stocks are holding nearly in place as Wall Street waits to hear where the Federal Reserve may be taking interest rates. The S&P 500 was little changed early Wednesday.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Verve Therapeutics remains an early-stage biotech, making the rally purely acquisition-driven, not based on fundamentals.

The plane maker is betting that demand for aircraft will continue to fuel growth in coming years. The systems will be jointly developed and produced by the two companies, with suppliers and industrial ...